[Matthew Schewel for Inside U.S. Trade] A confidential Trans-Pacific Partnership (TPP) negotiating document obtained by Inside U.S. Trade sheds new light on the extent of disagreement that remains over controversial provisions on intellectual property (IP) protection for pharmaceuticals, roughly three months ahead of a November target for producing a substantial outcome in the talks.
The two-page document, which outlines potential options, or “landing zones,” for resolving pharmaceutical IP issues, indicates that TPP countries have coalesced around a U.S. proposal under which less-developed members would be able to temporarily provide a lower standard of drug IP protection than more developed members.
But it shows that TPP countries are still at odds over the substantive obligations that would be required for each standard, as well as the mechanism for transitioning countries from the lower standard to the higher one.
Click here for the full story on Inside U.S. Trade.
QUT Media4th November 2025 The United Kingdom Parliament is considering a bill aimed at making smoking obsolete, which has been
Speaking at the Global Expert Network on Copyright User Rights Symposium on 16 June 2025, Professor Christophe Geiger argues for
On 25 September 2025, Professor Wend Wendland, delivered the 14th Peter Jaszi Distinguished Lecture at American University in Washington D.C..
On September 18, 2025, the Italian Senate definitively approved the country’s first comprehensive framework law on artificial intelligence (AI). The
Por Andrés Izquierdo Durante la segunda semana de agosto, fui invitado a hablar en la Feria Internacional del Libro de
By Andrés Izquierdo AI, Copyright, and the Future of Creativity: Notes from the Panama International Book FairDuring the second week